A landmark study of gender medicine is caught in an ethics row


A review of transgender medicine by Hilary Cass reveals weak scientific evidence supporting the use of puberty blockers and cross-sex hormones in teenagers, sparking an ethics debate.
AI Summary available — skim the key points instantly. Show AI Generated Summary
Show AI Generated Summary

ONE REASON that transgender medicine is such a fraught topic is that there is little evidence behind the arguments. When Hilary Cass, a British paediatrician, reviewed the field for an influential report published in 2024, she noted that most of the science underlying the prescription of puberty blockers and cross-sex hormones to teenagers (an approach called “gender-affirming care”) was “remarkably weak”.

Was this article displayed correctly? Not happy with what you see?

Tabs Reminder: Tabs piling up in your browser? Set a reminder for them, close them and get notified at the right time.

Try our Chrome extension today!


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device